Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioblastoma | 3 | 2022 | 91 | 1.020 |
Why?
|
STAT2 Transcription Factor | 1 | 2021 | 7 | 0.810 |
Why?
|
STAT1 Transcription Factor | 1 | 2021 | 26 | 0.800 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.800 |
Why?
|
DNA-Directed DNA Polymerase | 4 | 2021 | 92 | 0.470 |
Why?
|
Brain Neoplasms | 2 | 2023 | 286 | 0.330 |
Why?
|
Enzyme Inhibitors | 3 | 2019 | 391 | 0.300 |
Why?
|
G-Quadruplexes | 2 | 2021 | 80 | 0.300 |
Why?
|
Organoids | 2 | 2022 | 39 | 0.250 |
Why?
|
Pyrimidines | 2 | 2021 | 191 | 0.220 |
Why?
|
Vincristine | 1 | 2022 | 89 | 0.200 |
Why?
|
Janus Kinase 1 | 1 | 2021 | 17 | 0.200 |
Why?
|
Janus Kinase 2 | 1 | 2021 | 26 | 0.200 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2022 | 42 | 0.200 |
Why?
|
Nitriles | 1 | 2021 | 54 | 0.200 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 61 | 0.200 |
Why?
|
Indoles | 3 | 2019 | 278 | 0.200 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 99 | 0.190 |
Why?
|
Pyrans | 1 | 2021 | 22 | 0.190 |
Why?
|
Nucleotidyltransferases | 1 | 2021 | 14 | 0.190 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.190 |
Why?
|
Pyrazoles | 1 | 2021 | 113 | 0.190 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2021 | 78 | 0.180 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 103 | 0.180 |
Why?
|
DNA Replication | 1 | 2021 | 151 | 0.180 |
Why?
|
Cytoplasmic Dyneins | 1 | 2019 | 3 | 0.170 |
Why?
|
Transcriptome | 1 | 2021 | 313 | 0.170 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 71 | 0.160 |
Why?
|
DNA Damage | 2 | 2019 | 301 | 0.160 |
Why?
|
DNA | 1 | 2021 | 545 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 829 | 0.150 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 210 | 0.140 |
Why?
|
Apoptosis | 1 | 2022 | 1100 | 0.140 |
Why?
|
Cytoplasmic Granules | 1 | 2016 | 22 | 0.140 |
Why?
|
Polyubiquitin | 1 | 2016 | 3 | 0.140 |
Why?
|
Cytoplasm | 1 | 2016 | 90 | 0.130 |
Why?
|
Kynurenine | 1 | 2015 | 16 | 0.130 |
Why?
|
Cisplatin | 1 | 2018 | 278 | 0.130 |
Why?
|
Child | 3 | 2023 | 6824 | 0.130 |
Why?
|
Genomic Instability | 1 | 2015 | 92 | 0.130 |
Why?
|
Lysine | 1 | 2016 | 90 | 0.130 |
Why?
|
Neoplasms | 2 | 2023 | 1233 | 0.130 |
Why?
|
Humans | 13 | 2023 | 49827 | 0.120 |
Why?
|
Protein Biosynthesis | 1 | 2016 | 253 | 0.120 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 477 | 0.110 |
Why?
|
RNA, Messenger | 1 | 2016 | 1105 | 0.110 |
Why?
|
Cell Line, Tumor | 3 | 2022 | 1402 | 0.100 |
Why?
|
Young Adult | 1 | 2021 | 3936 | 0.100 |
Why?
|
Breast Neoplasms | 1 | 2021 | 1169 | 0.100 |
Why?
|
Oxidative Stress | 1 | 2016 | 768 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 2 | 2023 | 154 | 0.100 |
Why?
|
T-Lymphocytes | 2 | 2023 | 338 | 0.090 |
Why?
|
Adolescent | 1 | 2021 | 6340 | 0.090 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 1172 | 0.090 |
Why?
|
Adult | 2 | 2022 | 13160 | 0.080 |
Why?
|
Signal Transduction | 1 | 2015 | 1617 | 0.080 |
Why?
|
Models, Molecular | 2 | 2021 | 337 | 0.070 |
Why?
|
Cell Line | 2 | 2021 | 1002 | 0.070 |
Why?
|
Protein Binding | 2 | 2021 | 660 | 0.070 |
Why?
|
Female | 2 | 2021 | 26329 | 0.060 |
Why?
|
Monensin | 1 | 2022 | 12 | 0.050 |
Why?
|
Microtubules | 1 | 2022 | 41 | 0.050 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 151 | 0.050 |
Why?
|
bcl-2-Associated X Protein | 1 | 2022 | 56 | 0.050 |
Why?
|
Caspase 3 | 1 | 2022 | 97 | 0.050 |
Why?
|
Mitosis | 1 | 2022 | 92 | 0.050 |
Why?
|
Male | 1 | 2021 | 25093 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2022 | 276 | 0.050 |
Why?
|
MCF-7 Cells | 1 | 2021 | 68 | 0.050 |
Why?
|
Nucleotide Motifs | 1 | 2021 | 24 | 0.050 |
Why?
|
Cell Cycle | 1 | 2022 | 232 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 136 | 0.050 |
Why?
|
Genes, myc | 1 | 2021 | 40 | 0.050 |
Why?
|
Cell Division | 1 | 2021 | 292 | 0.050 |
Why?
|
Drug Discovery | 1 | 2021 | 85 | 0.050 |
Why?
|
Cell Movement | 1 | 2021 | 247 | 0.040 |
Why?
|
Alkylation | 1 | 2019 | 11 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2019 | 30 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 1 | 2019 | 76 | 0.040 |
Why?
|
Radiation, Ionizing | 1 | 2019 | 100 | 0.040 |
Why?
|
Chromatin | 1 | 2019 | 152 | 0.040 |
Why?
|
DNA Repair | 1 | 2019 | 192 | 0.040 |
Why?
|
Thiobarbiturates | 1 | 2018 | 23 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2018 | 73 | 0.040 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 68 | 0.040 |
Why?
|
Scattering, Small Angle | 1 | 2016 | 1 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 43 | 0.030 |
Why?
|
Ubiquitination | 1 | 2016 | 43 | 0.030 |
Why?
|
HeLa Cells | 1 | 2016 | 251 | 0.030 |
Why?
|
Protein Conformation | 1 | 2016 | 166 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 244 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 465 | 0.030 |
Why?
|
Mutation | 1 | 2021 | 1293 | 0.030 |
Why?
|
Molecular Structure | 1 | 2015 | 297 | 0.030 |
Why?
|
Binding Sites | 1 | 2016 | 377 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2015 | 394 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 436 | 0.030 |
Why?
|